Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals, will provide a company overview at the Jefferies 2010 Global Life Sciences Conference in New York City.
(PRWEB) June 3, 2010 -- Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference in New York City. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 11:00am EST, Wednesday, June 9, 2010 at the Grand Hyatt in New York City, New York.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com, http://www.merrimackpharma.com
Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy(at)raymondstevenson(dot)com
# # #
Read the full story at http://www.prweb.com/releases/2010/06/prweb4064064.htm.
Copyright©2010 Vocus, Inc.
All rights reserved